Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Dr. Voodoo who wrote (2102)	1/28/1998 5:11:00 PM
From: Bill Wexler	Read Replies (2) \| Respond to of 7041

<<For instance I can go make sildenafil and a half a dozen thousand other drugs pretty easily and I'm just ANY old chemist.>> Correct. I felt that Zonagen was attempting to fraudulently promote its "unique formulation" claim. I wanted to point out that neither the ingredients, the delivery method nor the manufacturing processes are "unique". Vasomax is simply 40 mg of Phentolamine, a lot of lactose, and some other bulk. In fact, it seems that Zonagen is basing its entire claim on the addition of 16 mg of croscarmellose sodium... asensio.com

To: Dr. Voodoo who wrote (2102)	1/28/1998 7:47:00 PM
From: Cacaito	Read Replies (2) \| Respond to of 7041

Dr. Voodoo, Grant Gwinup published in 1988 about oral phentolamine, before Zorgniotti (1994). Zorgniotti quoted Gwinup in his work and his patent (sold later to Zonagen). Could Gwinup come back later and claim his "invention"? Anyway, the more succesful phentolamine is, the more generics will go after then. But even if the generics are succesful there will be some time left for Zonagen to rise. The patent merits is not a big deal, except long term. The main question is: does phantolamine produces an erection in organic ED? One could make the case that, viagra ahead, and the NDA in slow progress maybe Zonagen will try to keep some fire and published something in a journal. (not more PR). If they have such a good patent protection in the making why not do good to the investors (not the flimsy buyback, which is not working)but get real data out.